| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Biomarkers
|
Upadhyay, Shweta
|
|
2013
|
27 |
1 |
p. 19-31
13 p.
|
artikel
|
| 2 |
Clinical Scoring Tools
|
Wiemken, Timothy
|
|
2013
|
27 |
1 |
p. 33-48
16 p.
|
artikel
|
| 3 |
Contents
|
|
|
2013
|
27 |
1 |
p. vii-xi
nvt p.
|
artikel
|
| 4 |
Contributors
|
|
|
2013
|
27 |
1 |
p. iii-v
nvt p.
|
artikel
|
| 5 |
Does Empirical Therapy with a Fluoroquinolone or the Combination of a β-Lactam Plus a Macrolide Result in Better Outcomes for Patients Admitted to the General Ward?
|
Ruhe, Jörg
|
|
2013
|
27 |
1 |
p. 115-132
18 p.
|
artikel
|
| 6 |
Does Empiric Therapy for Atypical Pathogens Improve Outcomes for Patients with CAP?
|
File Jr., Thomas M.
|
|
2013
|
27 |
1 |
p. 99-114
16 p.
|
artikel
|
| 7 |
Erratum
|
|
|
2013
|
27 |
1 |
p. xv-
1 p.
|
artikel
|
| 8 |
Forthcoming Issues
|
|
|
2013
|
27 |
1 |
p. xii-
1 p.
|
artikel
|
| 9 |
Guidelines and Quality Measures
|
Johnstone, Jennie
|
|
2013
|
27 |
1 |
p. 71-86
16 p.
|
artikel
|
| 10 |
How Effective is Vaccination in Preventing Pneumococcal Disease?
|
Musher, Daniel M.
|
|
2013
|
27 |
1 |
p. 229-241
13 p.
|
artikel
|
| 11 |
How Important Are Anaerobic Bacteria in Aspiration Pneumonia
|
Bartlett, John G.
|
|
2013
|
27 |
1 |
p. 149-155
7 p.
|
artikel
|
| 12 |
How Important is Methicillin-Resistant Staphylococcus aureus as a Cause of Community-Acquired Pneumonia and What is Best Antimicrobial Therapy?
|
Wunderink, Richard G.
|
|
2013
|
27 |
1 |
p. 177-188
12 p.
|
artikel
|
| 13 |
Index
|
|
|
2013
|
27 |
1 |
p. 243-252
10 p.
|
artikel
|
| 14 |
Is the Present Definition of Health Care–Associated Pneumonia the Best Way to Define Risk of Infection with Antibiotic-Resistant Pathogens?
|
Yap, Vanessa
|
|
2013
|
27 |
1 |
p. 1-18
18 p.
|
artikel
|
| 15 |
Preface
|
File Jr., Thomas M.
|
|
2013
|
27 |
1 |
p. xiii-xiv
nvt p.
|
artikel
|
| 16 |
What is the Association of Cardiovascular Events with Clinical Failure in Patients with Community-Acquired Pneumonia?
|
Peyrani, Paula
|
|
2013
|
27 |
1 |
p. 205-210
6 p.
|
artikel
|
| 17 |
What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents)
|
Sibila, Oriol
|
|
2013
|
27 |
1 |
p. 133-147
15 p.
|
artikel
|
| 18 |
What Is the Best Approach to the Nonresponding Patient with Community-Acquired Pneumonia?
|
Sialer, Salvador
|
|
2013
|
27 |
1 |
p. 189-203
15 p.
|
artikel
|
| 19 |
What Is the Relevance of Antimicrobial Resistance on the Outcome of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae? (Should Macrolide Monotherapy Be Used for Mild Pneumonia?)
|
Low, Donald E.
|
|
2013
|
27 |
1 |
p. 87-97
11 p.
|
artikel
|
| 20 |
What is the Role of Antimicrobial Stewardship in Improving Outcomes of Patients with CAP?
|
Nussenblatt, Veronique
|
|
2013
|
27 |
1 |
p. 211-228
18 p.
|
artikel
|
| 21 |
What Is the Role of Newer Molecular Tests in the Management of CAP?
|
Gaydos, Charlotte A.
|
|
2013
|
27 |
1 |
p. 49-69
21 p.
|
artikel
|
| 22 |
What is the Role of Respiratory Viruses in Community-Acquired Pneumonia?
|
Pavia, Andrew T.
|
|
2013
|
27 |
1 |
p. 157-175
19 p.
|
artikel
|
Tijdschrift beschrijving